0B68 Squires, Kathleen - Thomas Jefferson University - Thomas Jefferson University
key018

Kathleen Squires, MD

Contact Dr. Squires

1015 Chestnut Street
Suite 1020
Philadelphia, PA 19107

(215) 955-7785
(215) 955-9362 fax

Most Recent Peer-reviewed Publications

  1. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women
  2. Bone health and human immunodeficiency virus infection
  3. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK study
  4. Insights on GRACE (Gender, Race, and Clinical Experience) from the patient's perspective: GRACE participant survey
  5. Inflammatory biomarker changes and their correlation with framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES
  6. Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.
  7. Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination
  8. Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-Week outcomes from GRACE
  9. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women
  10. Gender-sensitive reporting in medical research
  11. Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women
  12. ARIES 144 week results: Durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine
  13. Health-related quality of life in the gender, race, and clinical experience trial
  14. Prevalence of obstructive lung disease in HIV population: A cross sectional study
  15. Recruitment and retention of diverse populations in antiretroviral clinical trials: Practical applications from the Gender, Race and Clinical Experience study
  16. Health needs of HIV-infected women in the United States: Insights from the women living positive survey
  17. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
  18. Letter in response to the new SHEA guideline for healthcare workers with hepatitis B Virus, hepatitis C virus, and/or human immunodeficiency virus
  19. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus
  20. Sex-based outcomes of Darunavir-Ritonavir therapy: A single-group trial
0